Free Trial
NASDAQ:PODD

Insulet (PODD) Stock Price, News & Analysis

Insulet logo
$301.62 +1.63 (+0.54%)
Closing price 07/2/2025 04:00 PM Eastern
Extended Trading
$312.52 +10.91 (+3.62%)
As of 07/2/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Insulet Stock (NASDAQ:PODD)

Key Stats

Today's Range
$297.29
$304.38
50-Day Range
$250.25
$327.47
52-Week Range
$173.00
$329.33
Volume
883,993 shs
Average Volume
718,044 shs
Market Capitalization
$21.23 billion
P/E Ratio
54.25
Dividend Yield
N/A
Price Target
$321.00
Consensus Rating
Moderate Buy

Company Overview

Insulet Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
85th Percentile Overall Score

PODD MarketRank™: 

Insulet scored higher than 85% of companies evaluated by MarketBeat, and ranked 175th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Insulet has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 15 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Insulet has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Insulet's stock forecast and price target.
  • Earnings Growth

    Earnings for Insulet are expected to grow by 26.79% in the coming year, from $3.92 to $4.97 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Insulet is 54.25, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.28.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Insulet is 54.25, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.19.

  • Price to Earnings Growth Ratio

    Insulet has a PEG Ratio of 2.68. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Insulet has a P/B Ratio of 17.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Insulet's valuation and earnings.
  • Percentage of Shares Shorted

    2.72% of the float of Insulet has been sold short.
  • Short Interest Ratio / Days to Cover

    Insulet has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Insulet has recently increased by 0.53%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Insulet does not currently pay a dividend.

  • Dividend Growth

    Insulet does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.72% of the float of Insulet has been sold short.
  • Short Interest Ratio / Days to Cover

    Insulet has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Insulet has recently increased by 0.53%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Insulet has a news sentiment score of 1.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.90 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 19 news articles for Insulet this week, compared to 14 articles on an average week.
  • Search Interest

    Only 10 people have searched for PODD on MarketBeat in the last 30 days. This is a decrease of -9% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Insulet insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,680,885.00 in company stock.

  • Percentage Held by Insiders

    Only 0.39% of the stock of Insulet is held by insiders.

  • Read more about Insulet's insider trading history.
Receive PODD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Insulet and its competitors with MarketBeat's FREE daily newsletter.

PODD Stock News Headlines

Top-Performing MedTech Stocks in 2025 - This image is an original composition by MarketBeat using licensed and editorial elements. Not for redistribution or reuse.
3 Medical Technology Stocks Outperforming in 2025
Three med-tech stocks, TransMedics, Insulet, and GRAIL, are outperforming the market and their sector while forming bullish technical patterns.
I was wrong about Trump
I made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.
See More Headlines

PODD Stock Analysis - Frequently Asked Questions

Insulet's stock was trading at $261.07 at the start of the year. Since then, PODD stock has increased by 15.5% and is now trading at $301.62.
View the best growth stocks for 2025 here
.

Insulet Corporation (NASDAQ:PODD) announced its quarterly earnings data on Thursday, May, 8th. The medical instruments supplier reported $1.02 EPS for the quarter, topping analysts' consensus estimates of $0.81 by $0.21. Insulet's revenue for the quarter was up 28.8% compared to the same quarter last year.
Read the conference call transcript
.

Shares of PODD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Insulet investors own include Predictive Oncology (POAI), JPMorgan Chase & Co. (JPM), Abbott Laboratories (ABT), Ford Motor (F), Bank of America (BAC), Wayfair (W) and Wells Fargo & Company (WFC).

Company Calendar

Last Earnings
5/08/2025
Today
7/02/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED PRODUCTS
Sub-Industry
Health Care Equipment
Current Symbol
NASDAQ:PODD
Employees
3,900
Year Founded
2000

Price Target and Rating

Average Stock Price Target
$321.00
High Stock Price Target
$380.00
Low Stock Price Target
$223.00
Potential Upside/Downside
+6.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
18 Analysts

Profitability

Trailing P/E Ratio
54.25
Forward P/E Ratio
76.94
P/E Growth
2.68
Net Income
$418.30 million
Pretax Margin
13.34%

Debt

Sales & Book Value

Annual Sales
$2.07 billion
Cash Flow
$4.46 per share
Price / Cash Flow
67.62
Book Value
$17.27 per share
Price / Book
17.46

Miscellaneous

Free Float
70,101,000
Market Cap
$21.23 billion
Optionable
Optionable
Beta
1.35

Social Links

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

This page (NASDAQ:PODD) was last updated on 7/3/2025 by MarketBeat.com Staff
From Our Partners